BIOHIT OYJ’S OPTION SCHEMES I 2013 AND II 2013 – TERMS UPDATE AND MANAGEMENT TEAM OPTION ARRANGEMENT
Biohit Oyj October 10, 2013 at 5:15 P.M. local time (EET)
Biohit Oyj’s Board of Directors has on October 10, 2013 decided to distribute in total 60.000 option rights in class I 2013A of the option scheme I 2013 to the members of the company management team as follows, excluding the CEO: Hendolin Panu 12.000 pcs, Mattila Jaana 12.000 pcs, Mickels Anu 12.000 pcs, Paloheimo Lea 12.000 pcs and Syrjänen Kari 12.000 pcs. For option rights in this class share subscription period commences on June 1, 2014 and ends on May 31, 2019.
In addition, the Board of Directors has decided to amend the conditions of both the scheme I 2013 and II 2013 so that 0.17 euros from the subscription price is recorded in the share capital. Correspondingly, the subscription price shall be at least 0.17 euros.
The terms and conditions of the option schemes are in full enclosed and also available on Biohit Oyj’s home pages: www.biohithealthcare.com/investors/corporate-governance
Biohit Oyj
Board of Directors
Attachment: Updated terms of Biohit Oyj’s Option Schemes I 2013 and II 2013 (pdf)
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission is "Innovating for Health". The purpose of the company is to take social responsibility and produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve the quality of life of people by preventing disease, human suffering and financial loss. We are committed to social responsibility and it is our duty to spread knowledge about the Group I human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki, Finland and its subsidiaries are located in China, Italy and the United Kingdom. Since 1999, Biohit's series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector. www.biohithealthcare.com